{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:29:23Z","timestamp":1790015363628,"version":"4.0.1"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objective<\/jats:title>\n                    <jats:p>Pregabalin (PGB) and duloxetine (DLX) are commonly used first-line medications in the clinical management of painful diabetic neuropathy (PDN), yet high-quality comparative evidence is limited. This meta-analysis evaluates the comparative efficacy and safety of PGB versus DLX, focusing on efficacy outcomes such as pain reduction and mental health, and safety outcomes including adverse events in PDN patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We searched electronic databases for relevant studies assessing the efficacy and safety of PGB and DLX in PDN. The primary outcomes were the mean change of the Visual Analog Scale (VAS) and the improvement ratio for patients achieving \u2265 50% pain reduction. Secondary outcomes include the Numeric Rating Scale (NRS) for pain, the Short Form 12 Health Survey (SF-12), and related adverse events. A random-effects meta-analysis was performed to evaluate these outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We analyzed 19 studies involving 4483 patients. PGB significantly reduced VAS scores at 24\u2009weeks (MD\u2009=\u2009-0.38; 95% confidence interval [CI], -0.45 to -0.31; P\u2009&amp;lt;\u2009.0001) and decreased the mental component of SF-12 compared to DLX (MD\u2009=\u2009-3.36; 95% CI, -6.64 to -0.07; P\u2009=\u2009.05) and similar rates of achieving &amp;gt;50% pain reduction (risk ratio = 0.91; 95% CI, 0.81 to 1.03; P\u2009=\u2009.13). Regarding safety, PGB showed a lower incidence of several adverse events, including anorexia, decreased appetite, diarrhea, nausea, and vomiting. However, no significant differences in VAS scores were observed between PGB and DLX at 1\u2009week, 2\u2009weeks, 4\u2009weeks, 6\u2009weeks, 8\u2009weeks, and 12\u2009weeks, with similar results observed in NRS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We found that PGB and DLX showed similar efficacy in relieving PDN. Ultimately, the 2 drugs\u2019 similar effectiveness and different safety profiles highlight the importance of considering patient-specific factors when choosing the appropriate treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/pm\/pnaf155","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T16:17:21Z","timestamp":1762791441000},"page":"574-592","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of pregabalin and duloxetine in painful diabetic neuropathy: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8938-5723","authenticated-orcid":false,"given":"Ahmed","family":"Mansour","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Al-Azhar University , Cairo,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7065-381X","authenticated-orcid":false,"given":"Ahmed Mostafa","family":"Amin","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Azhar University , Cairo,","place":["Egypt"]},{"name":"Medical Research Group of Egypt, Negida Academy , Arlington, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5802-2291","authenticated-orcid":false,"given":"Ahmed","family":"Farid Gadelmawla","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Menoufia University , Cairo,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9033-7494","authenticated-orcid":false,"given":"Ahmed","family":"Elbataa","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Azhar University , Cairo,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9111-320X","authenticated-orcid":false,"given":"Anas","family":"Mansour","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Azhar University , Cairo,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Ismail","family":"Elnady","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Kafr Elsheikh University , Kafr Elsheikh,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ashraf","family":"Husain","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Azhar University , Cairo,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Abdulrahman","family":"Saad","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Azhar University , Cairo,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3858-7563","authenticated-orcid":false,"given":"Amr","family":"Elshahat","sequence":"additional","affiliation":[{"name":"Departmment of Radiology, Yale University , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5101-5972","authenticated-orcid":false,"given":"Abdallah","family":"Abbas","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Azhar University , Damietta,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elshahat","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Azhar University , Cairo,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Mahmoud","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Azhar University , Cairo,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohaila Mansour","family":"Abdelsatar","sequence":"additional","affiliation":[{"name":"Faculty of Nursing, Beni-Suef National University , Beni-Suef,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Yasser","family":"Elnaggar","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Mansoura University , Mansoura,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman E","family":"Fayk","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Azhar University , Cairo,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah Farahat","family":"Elbanna","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Azhar University , Cairo,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Abd-Elsayed","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University of Wisconsin School of Medicine and Public Health , Madison, WI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"2026080312263232400_pnaf155-B1","doi-asserted-by":"crossref","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"2026080312263232400_pnaf155-B2","doi-asserted-by":"crossref","first-page":"588","DOI":"10.2337\/dc24-2287","article-title":"Understanding the impact of diabetic peripheral neuropathy and neuropathic pain on quality of life and mental health in 6,960 people with diabetes","volume":"48","author":"Borbjerg","year":"2025","journal-title":"Diabetes Care"},{"key":"2026080312263232400_pnaf155-B3","doi-asserted-by":"crossref","first-page":"e0211449","DOI":"10.1371\/journal.pone.0211449","article-title":"Is health related quality of life influenced by diabetic neuropathic pain among type II diabetes mellitus patients in Ethiopia?","volume":"14","author":"Degu","year":"2019","journal-title":"PLoS One"},{"key":"2026080312263232400_pnaf155-B4","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jpainsymman.2005.04.009","article-title":"Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep","volume":"30","author":"Gore","year":"2005","journal-title":"J Pain Symptom Manage"},{"key":"2026080312263232400_pnaf155-B5","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2147\/JPR.S451006","article-title":"A systematic guideline by the ASPN Workgroup on the evidence, education, and treatment algorithm for painful diabetic neuropathy: SWEET","volume":"17","author":"Sayed","year":"2024","journal-title":"J Pain Res"},{"key":"2026080312263232400_pnaf155-B6","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1097\/j.pain.0000000000001378","article-title":"A cross-sectional study investigating frequency and features of definitely diagnosed diabetic painful polyneuropathy","volume":"159","author":"Truini","year":"2018","journal-title":"Pain"},{"key":"2026080312263232400_pnaf155-B7","doi-asserted-by":"crossref","first-page":"110602","DOI":"10.1016\/j.diabres.2023.110602","article-title":"Prevalence of painful diabetic peripheral neuropathy in type 2 diabetes mellitus and diabetic peripheral neuropathy: a nationwide cross-sectional study in mainland China","volume":"198","author":"Li","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"2026080312263232400_pnaf155-B8","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(22)01472-6","article-title":"Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial","volume":"400","author":"Tesfaye","year":"2022","journal-title":"The Lancet"},{"key":"2026080312263232400_pnaf155-B9","first-page":"226","article-title":"Diabetic peripheral neuropathy: prevention and treatment","volume":"109","author":"Bragg","year":"2024","journal-title":"Am Fam Physician"},{"key":"2026080312263232400_pnaf155-B10","doi-asserted-by":"crossref","first-page":"S252","DOI":"10.2337\/dc25-S012","article-title":"12. Retinopathy, neuropathy, and foot care: standards of care in diabetes\u20142025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026080312263232400_pnaf155-B11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/YIC.0b013e3282f41d7e","article-title":"Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine","volume":"23","author":"Trivedi","year":"2008","journal-title":"Int Clin Psychopharmacol"},{"key":"2026080312263232400_pnaf155-B12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fphar.2011.00028","article-title":"Alpha 2 delta ligands, gabapentin and pregabalin: what is the evidence for potential use of these ligands in irritable bowel syndrome","volume":"2","author":"Gale","year":"2011","journal-title":"Front Pharmacol"},{"key":"2026080312263232400_pnaf155-B13","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.pain.2004.05.001","article-title":"Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial","volume":"110","author":"Rosenstock","year":"2004","journal-title":"Pain"},{"key":"2026080312263232400_pnaf155-B14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/aas.12420","article-title":"Efficacy and safety of pregabalin for treating painful diabetic peripheral neuropathy: a meta-analysis","volume":"59","author":"Zhang","year":"2015","journal-title":"Acta Anaesthesiol Scand"},{"key":"2026080312263232400_pnaf155-B15","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1212\/01.wnl.0000240225.04000.1a","article-title":"A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain","volume":"67","author":"Wernicke","year":"2006","journal-title":"Neurology"},{"key":"2026080312263232400_pnaf155-B16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13643-023-02185-6","article-title":"Efficacy and safety of duloxetine in painful diabetic peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Wu","year":"2023","journal-title":"Syst Rev"},{"key":"2026080312263232400_pnaf155-B17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1474-4422(25)00068-7","article-title":"Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis","volume":"24","author":"Soliman","year":"2025","journal-title":"Lancet Neurol"},{"key":"2026080312263232400_pnaf155-B18","doi-asserted-by":"crossref","first-page":"N 71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026080312263232400_pnaf155-B19","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions, Version 6.5 (Updated August 2024)","author":"Higgins","year":"2024"},{"key":"2026080312263232400_pnaf155-B20","doi-asserted-by":"crossref","first-page":"L4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026080312263232400_pnaf155-B21","volume-title":"Health Disparities in Quality Indicators of Healthcare Among Adults with Mental Illness","author":"Gierisch","year":"2014"},{"key":"2026080312263232400_pnaf155-B22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12874-024-02356-6","article-title":"Meta-analysis accelerator: a comprehensive tool for statistical data conversion in systematic reviews with meta-analysis","volume":"24","author":"Abbas","year":"2024","journal-title":"BMC Med Res Methodol"},{"key":"2026080312263232400_pnaf155-B23","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/ije\/dyn065","article-title":"Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation","volume":"37","author":"Patsopoulos","year":"2008","journal-title":"Int J Epidemiol"},{"key":"2026080312263232400_pnaf155-B24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11325-024-03163-5","article-title":"Efficacy and safety of sodium oxybate treatment in adults with narcolepsy and cataplexy: a systematic review and meta-analysis","volume":"29","author":"Amin","year":"2024","journal-title":"Sleep Breath"},{"key":"2026080312263232400_pnaf155-B25","doi-asserted-by":"publisher","first-page":"e69229","DOI":"10.7759\/cureus.69229","article-title":"Empagliflozin effect on left cardiac parameters in acute coronary syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Eljadid","year":"2024","journal-title":"Cureus"},{"key":"2026080312263232400_pnaf155-B26","doi-asserted-by":"crossref","first-page":"100431","DOI":"10.1016\/j.phanu.2025.100431","article-title":"Omega-3 supplementation in migraine prophylaxis: an updated systematic review and meta-analysis","volume":"31","author":"Sabet","year":"2025","journal-title":"PharmaNutrition"},{"key":"2026080312263232400_pnaf155-B27","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.2337\/dc12-0656","article-title":"Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain","volume":"35","author":"Boyle","year":"2012","journal-title":"Diabetes Care"},{"key":"2026080312263232400_pnaf155-B28","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.14260\/jemds\/2016\/476","article-title":"A prospective, randomized, comparative study of efficacy and safety of pregabalin, duloxetine and amitriptyline in patients of painful diabetic neuropathy in a tertiary care teaching hospital in rural Bengal","volume":"5","author":"Chakrabarty","year":"2016","journal-title":"JEMDS"},{"key":"2026080312263232400_pnaf155-B29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4103\/0253-7613.91867","article-title":"Evaluation of efficacy and safety of gabapentin, duloxetine, and pregabalin in patients with painful diabetic peripheral neuropathy","volume":"44","author":"Devi","year":"2012","journal-title":"Indian J Pharmacol"},{"key":"2026080312263232400_pnaf155-B30","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2147\/JPR.S170646","article-title":"Duloxetine in patients with diabetic peripheral neuropathic pain in Japan: a randomized, doubleblind, noninferiority comparative study with pregabalin","volume":"11","author":"Enomoto","year":"2018","journal-title":"J Pain Res"},{"key":"2026080312263232400_pnaf155-B31","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/AJP.0000000000000057","article-title":"Effectiveness of duloxetine compared with pregabalin and gabapentin in diabetic peripheral neuropathic pain: results from a German observational study","volume":"30","author":"Happich","year":"2014","journal-title":"Clin J Pain"},{"key":"2026080312263232400_pnaf155-B32","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40200-019-00427-w","article-title":"Efficacy and safety of duloxetine and pregabalin in Iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial","volume":"18","author":"Joharchi","year":"2019","journal-title":"J Diabetes Metab Disord"},{"key":"2026080312263232400_pnaf155-B33","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ejp.763","article-title":"Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy?","volume":"20","author":"Marchettini","year":"2016","journal-title":"Eur J Pain"},{"key":"2026080312263232400_pnaf155-B34","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3109\/00207454.2011.582238","article-title":"Retrospective chart review of duloxetine and pregabalin in the treatment of painful neuropathy","volume":"121","author":"Mittal","year":"2011","journal-title":"Int J Neurosci"},{"key":"2026080312263232400_pnaf155-B35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.33314\/jnhrc.v22i01.5120","article-title":"Amitriptyline, pregabalin and duloxetine for treatment of painful diabetic peripheral neuropathy","volume":"22","author":"Nepal","year":"2024","journal-title":"J Nepal Health Res Counc"},{"key":"2026080312263232400_pnaf155-B36","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3390\/ph16071017","article-title":"Efficacy of pregabalin and duloxetine in patients with Painful Diabetic Peripheral Neuropathy (PDPN): a multi-centre phase IV clinical trial\u2014BLOSSOM","volume":"16","author":"Rakusa","year":"2023","journal-title":"Pharmaceuticals"},{"key":"2026080312263232400_pnaf155-B37","first-page":"71","article-title":"Comparison of safety and efficacy of pregabalin, duloxetine and their combination with epalrestat in diabetic neuropathy: a prospective, double-blind, randomized, controlled Trial","volume":"11","author":"Singh","year":"2021","journal-title":"J Appl Pharm Sci"},{"key":"2026080312263232400_pnaf155-B38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.dsx.2016.07.003","article-title":"A study on comparative efficacy and cost effectiveness of pregabalin and duloxetine used in diabetic neuropathic pain","volume":"11","author":"Roy","year":"2017","journal-title":"Diabetes Metab Syndr"},{"key":"2026080312263232400_pnaf155-B39","first-page":"834","article-title":"Comparison of efficacy of pregabalin vs duloxetine in peripheral neuropathy pain in type 2 diabetic patients at low doses","volume":"16","author":"Shabbir","year":"2022","journal-title":"PJMHS"},{"key":"2026080312263232400_pnaf155-B40","first-page":"e28683","article-title":"A prospective observational study comparing the efficacy and safety of duloxetine and pregabalin in diabetic peripheral neuropathic pain","volume":"14","author":"Shah","year":"2022","journal-title":"Cureus"},{"key":"2026080312263232400_pnaf155-B41","first-page":"e5293","article-title":"Comparison of the efficacy of duloxetine and pregabalin in pain relief associated with diabetic neuropathy","volume":"11","author":"Shahid","year":"2019","journal-title":"Cureus"},{"key":"2026080312263232400_pnaf155-B42","doi-asserted-by":"crossref","first-page":"615","DOI":"10.4065\/mcp.2010.0681","article-title":"Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison","volume":"86","author":"Tanenberg","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"2026080312263232400_pnaf155-B43","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.pain.2013.05.043","article-title":"Duloxetine and pregabalin: high-dose monotherapy or their combination? The \u201cCOMBO-DN study\u201d: a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain","volume":"154","author":"Tesfaye","year":"2013","journal-title":"Pain"},{"key":"2026080312263232400_pnaf155-B44","doi-asserted-by":"crossref","first-page":"353","DOI":"10.12688\/f1000research.130345.1","article-title":"Fixed dose combination of low dose pregabalin and duloxetine, or pregabalin monotherapy for neuropathic pain: a double-blind, randomized, parallel-group study","volume":"12","author":"Krishnaprasad","year":"2023","journal-title":"F1000Res"},{"key":"2026080312263232400_pnaf155-B45","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2377-9-6","article-title":"Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain","volume":"9","author":"Quilici","year":"2009","journal-title":"BMC Neurol"},{"key":"2026080312263232400_pnaf155-B46","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol"},{"key":"2026080312263232400_pnaf155-B47","first-page":"e1","article-title":"Relative efficacy and safety of pharmacotherapeutic interventions for diabetic peripheral neuropathy: a systematic review and Bayesian network meta-analysis","volume":"24","author":"Asrar","year":"2021","journal-title":"Pain Physician"},{"key":"2026080312263232400_pnaf155-B48","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.2147\/JPR.S138099","article-title":"Combination treatment of neuropathic pain: Danish expert recommendations based on a DELPHI process","volume":"10","author":"Holbech","year":"2017","journal-title":"J Pain Res"},{"key":"2026080312263232400_pnaf155-B49","first-page":"316","article-title":"Amitriptyline, duloxetine, and pregabalin each effective in decreasing pain from diabetic peripheral neuropathy; combinations even better","volume":"107","author":"Barry","year":"2023","journal-title":"Am Fam Physician"},{"key":"2026080312263232400_pnaf155-B50","doi-asserted-by":"crossref","first-page":"554899","DOI":"10.3389\/fpsyt.2020.554899","article-title":"A systematic review of efficacy, safety, and tolerability of duloxetine","volume":"11","author":"Rodrigues-Amorim","year":"2020","journal-title":"Front Psychiatry"},{"key":"2026080312263232400_pnaf155-B51","doi-asserted-by":"crossref","first-page":"e023600","DOI":"10.1136\/bmjopen-2018-023600","article-title":"Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials","volume":"9","author":"Onakpoya","year":"2019","journal-title":"BMJ Open"},{"key":"2026080312263232400_pnaf155-B52","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/papr.12146","article-title":"A comprehensive drug safety evaluation of pregabalin in peripheral neuropathic pain","volume":"15","author":"Freynhagen","year":"2015","journal-title":"Pain Pract"},{"key":"2026080312263232400_pnaf155-B53","doi-asserted-by":"crossref","first-page":"154867","DOI":"10.1016\/j.metabol.2021.154867","article-title":"Management of diabetic neuropathy","volume":"123","author":"Cernea","year":"2021","journal-title":"Metabolism"},{"key":"2026080312263232400_pnaf155-B54","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev-med-043021-033114","article-title":"Spectrum of diabetic neuropathy: new insights in diagnosis and treatment","volume":"75","author":"Dillon","year":"2024","journal-title":"Annu Rev Med"},{"key":"2026080312263232400_pnaf155-B55","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s40261-023-01318-y","article-title":"Monotherapy versus combination therapy in the treatment of painful diabetic neuropathy: a systematic review and meta-analysis","volume":"43","author":"Medeiros Dantas","year":"2023","journal-title":"Clin Drug Investig"},{"key":"2026080312263232400_pnaf155-B56","doi-asserted-by":"crossref","first-page":"110765","DOI":"10.1016\/j.diabres.2023.110765","article-title":"Conventional management and current guidelines for painful diabetic neuropathy","volume":"206","author":"Tesfaye","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"2026080312263232400_pnaf155-B57","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.2337\/dc25-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026080312263232400_pnaf155-B58","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s40138-025-00316-y","article-title":"Pediatric pain management innovations: recent advancements in pain management techniques for pediatric patients in the emergency department: a narrative review","volume":"13","author":"Abo-elnour","year":"2025","journal-title":"Curr Emerg Hosp Med Rep"},{"key":"2026080312263232400_pnaf155-B59","doi-asserted-by":"crossref","first-page":"39","DOI":"10.7326\/0003-4819-155-1-201107050-00006","article-title":"Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study","volume":"155","author":"Dechartres","year":"2011","journal-title":"Ann Intern Med"},{"key":"2026080312263232400_pnaf155-B60","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.jacl.2025.04.081","article-title":"Sex differences in cardiovascular outcomes among patients with elevated lipoprotein(a)","volume":"19","author":"Abdelazeem","year":"2025","journal-title":"J Clin Lipidol"}],"container-title":["Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/painmedicine\/advance-article-pdf\/doi\/10.1093\/pm\/pnaf155\/65259923\/pnaf155.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/painmedicine\/article-pdf\/27\/5\/574\/65259923\/pnaf155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/painmedicine\/article-pdf\/27\/5\/574\/65259923\/pnaf155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:26:44Z","timestamp":1785774404000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/painmedicine\/article\/27\/5\/574\/8320008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":60,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,11,10]]},"published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/pm\/pnaf155","relation":{},"ISSN":["1526-2375","1526-4637"],"issn-type":[{"value":"1526-2375","type":"print"},{"value":"1526-4637","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2025,11,10]]}}}